AR042103A1 - Conjugados de hormona de crecimiento humana pegilados n- terminales y proceso para su preparacion - Google Patents

Conjugados de hormona de crecimiento humana pegilados n- terminales y proceso para su preparacion

Info

Publication number
AR042103A1
AR042103A1 ARP030104295A ARP030104295A AR042103A1 AR 042103 A1 AR042103 A1 AR 042103A1 AR P030104295 A ARP030104295 A AR P030104295A AR P030104295 A ARP030104295 A AR P030104295A AR 042103 A1 AR042103 A1 AR 042103A1
Authority
AR
Argentina
Prior art keywords
human growth
growth hormone
human
hgh
peg conjugate
Prior art date
Application number
ARP030104295A
Other languages
English (en)
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of AR042103A1 publication Critical patent/AR042103A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una hormona de crecimiento humana (hGH) modificada químicamente preparada uniendo un resto de polietilenglicol-butiraldehído a la fenilalanina N-terminal de la proteína. La proteína modificada químicamente puede tener una actividad hGH de mucha mayor duración que la hGH no modificada, posibilitando una dosis reducida y oportunidades de cambio de régimen. Reivindicación 1: Un conjugado de hormona de crecimiento humana-PEG caracterizado porque tiene la estructura de fórmula (1) o fórmula (2) en la que n es un número entero entre 1 y 10; m es un número entero entre 1 a y 10; R es una hormona de crecimiento humana u hormona de crecimiento humana metionilo. Reivindicación 8: Una composición caracterizada porque comprende el conjugado de hormona de crecimiento humano-PEG de las reivindicaciones 1, 2, 3, 4, 5, 6 o 7 y al menos un vehículo farmacéuticamente aceptable. Reivindicación 9: Un procedimiento de tratamiento de un paciente que tiene un trastorno de crecimiento o desarrollo, caracterizado porque comprende administrar a dicho paciente una cantidad terapéuticamente eficaz del conjugado hormona de crecimiento humana-PEG de las reivindicaciones 1, 2, ,3, 4, 5, 6, o 7.
ARP030104295A 2002-11-20 2003-11-20 Conjugados de hormona de crecimiento humana pegilados n- terminales y proceso para su preparacion AR042103A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42782302P 2002-11-20 2002-11-20

Publications (1)

Publication Number Publication Date
AR042103A1 true AR042103A1 (es) 2005-06-08

Family

ID=32825103

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104295A AR042103A1 (es) 2002-11-20 2003-11-20 Conjugados de hormona de crecimiento humana pegilados n- terminales y proceso para su preparacion

Country Status (9)

Country Link
US (1) US20040127417A1 (es)
AR (1) AR042103A1 (es)
GT (1) GT200300250A (es)
NL (3) NL1024831C2 (es)
PA (1) PA8588901A1 (es)
PE (1) PE20040797A1 (es)
SV (1) SV2004001674A (es)
TW (1) TWI281864B (es)
UY (1) UY28085A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US7157546B2 (en) 2002-09-09 2007-01-02 Nektar Therapeutics Al, Corporation Water-soluble polymer alkanals
ES2343518T3 (es) * 2002-09-09 2010-08-03 Hanall Biopharma Co., Ltd. Polipeptidos interferon alfa modificados resistentes a proteasas.
US20040136952A1 (en) * 2002-12-26 2004-07-15 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
EA008866B1 (ru) * 2002-12-26 2007-08-31 Маунтин Вью Фамэсьютикэлс, Инк. ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
US20070105770A1 (en) * 2004-01-21 2007-05-10 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
JP2007522198A (ja) * 2004-02-09 2007-08-09 ファルマシア コーポレーション 化学修飾されたヒト成長ホルモン受容体アンタゴニスト結合体
EP1805216A2 (en) * 2004-10-18 2007-07-11 Novo Nordisk A/S Growth hormone conjugates
JP2008517033A (ja) * 2004-10-18 2008-05-22 ノボ ノルディスク アクティーゼルスカブ オキシム、チアゾリジン、ジチアン、ジチオランまたはヒドラゾンが連結した成長ホルモンの類似体の作製方法
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
WO2006102659A2 (en) * 2005-03-23 2006-09-28 Nektar Therapeutics Al, Corporation CONJUGATES OF AN hGH MOIETY AND A POLYMER
EP1928906A2 (en) * 2005-08-30 2008-06-11 Novo Nordisk Health Care AG Liquid formulations of pegylated growth hormone
WO2007097934A2 (en) * 2006-02-17 2007-08-30 Elusys Therapeutics, Inc. Methods and compositions for using erythrocytes as carriers for delivery of drugs
KR20100014215A (ko) * 2006-07-07 2010-02-10 노보 노르디스크 헬스 케어 악티엔게젤샤프트 신규 단백질 접합체 및 그것의 제조 방법
US20090252703A1 (en) * 2006-10-19 2009-10-08 Gegg Jr Colin V Use of alcohol co-solvents to improve pegylation reaction yields
EP2157432A1 (en) * 2008-08-15 2010-02-24 Qiagen GmbH Method for analysing a complex sample by mass spectrometry
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
EP3355384A1 (en) * 2017-01-31 2018-08-01 Universite De Liege Flexible thin-films for battery electrodes
CN114539384B (zh) * 2020-11-19 2024-09-06 江苏众红生物工程创药研究院有限公司 聚乙二醇化长效生长激素及其制备方法和医药应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4342832A (en) * 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US5618697A (en) * 1982-12-10 1997-04-08 Novo Nordisk A/S Process for preparing a desired protein
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
JP2989002B2 (ja) * 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
JP3051145B2 (ja) * 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
JP3628333B2 (ja) * 1995-09-21 2005-03-09 ジェネンテック インコーポレーテッド ヒト成長ホルモン変異体
KR100731826B1 (ko) * 1999-01-14 2007-06-22 볼더 바이오테크놀로지 인코퍼레이티드 유리 시스테인 잔기를 함유하는 단백질의 제조 방법
SE9904502D0 (sv) * 1999-12-09 1999-12-09 Pharmacia & Upjohn Ab Production of peptides

Also Published As

Publication number Publication date
NL1028837A1 (nl) 2005-08-30
TW200418878A (en) 2004-10-01
NL1032282A1 (nl) 2006-11-07
GT200300250A (es) 2004-08-18
TWI281864B (en) 2007-06-01
US20040127417A1 (en) 2004-07-01
UY28085A1 (es) 2004-07-30
SV2004001674A (es) 2004-05-17
NL1032282C2 (nl) 2007-03-09
PE20040797A1 (es) 2004-12-10
NL1024831A1 (nl) 2004-05-26
PA8588901A1 (es) 2005-02-04
NL1028837C2 (nl) 2006-08-14
NL1024831C2 (nl) 2005-04-28

Similar Documents

Publication Publication Date Title
AR042103A1 (es) Conjugados de hormona de crecimiento humana pegilados n- terminales y proceso para su preparacion
AR017780A1 (es) Conjugado del factor de liberacion de hormona de crecimiento-polietilenenglicol (hgrf-peg) y metodo para la preparacion en sitio-especifico del mismo.
CY1106723T1 (el) Ν-τελικα μονοπεγυλιωμενα συζευγματα ανθρωπινης αυξητικης ορμονης, διεργασιες για την παρασκευη τους και μεθοδοι χρησης αυτων
JPH05505808A (ja) 創傷の治癒を促進するためへの銅(2)含有化合物の使用
HRP20020787B1 (en) Method of treatment using ligand-immunogen conjugates
CY1119369T1 (el) Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της αλφα-γαλακτοσιδασης α
GEP20063860B (en) Chemically-modified human growth hormone conjugates
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
KR101831465B1 (ko) 단백질 결합 프로드러그를 갖는 약물 조합
ES2227527T3 (es) Un factor de crecimiento de queratinocitos (kgf) truncado que tiene actividad biologica aumentada.
AR006598A1 (es) "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
CY1106283T1 (el) Κινολινυλ-πυρρολοπυραζολες
BR9510168A (pt) Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição
MX9700552A (es) Conjugados de vitamina b12 y proteinas.
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
EA200200194A1 (ru) Антагонисты хемокинного рецептора и способы их применения
NO20024646L (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
DE69914084D1 (de) Phenylacetylglutamin, phenylacetylisoglutamin, und/oder phenylacetat zur behandlung von neoplastischen erkrankungen
DE60137146D1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
DE69924304D1 (de) N-palmitoylethanolamid-enthaltende pharmazeutische zusammensetzungen und deren verwendung in der veterinärmedizin
AR002018A1 (es) Derivado de benzotiepina opticamente activo; metodo para producirlo; compuesto opticamente activo de uso en dicho metodo; promotor deosteogenesis, agente para prevenir o tratar enfermedades del hueso, promotor para el tratamiento de la fractura de hueso, metodo de tratamiento y
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
ATE179618T1 (de) Pharmazeutische zusammensetzungen, enthaltende polymerverbundene anthracycline-glykosiden, und verfahren zu deren herstellung
PE20000131A1 (es) Derivados de acidos fenilaminoalquilcarboxilicos y composiciones farmaceuticas que los comprenden
ATE549036T1 (de) Thymosin-alpha-1-peptid/polymer-konjugate

Legal Events

Date Code Title Description
FB Suspension of granting procedure